OX118

OX118 is a fully human anti-OX40L IgG1 monoclonal antibody in development for the treatment of immune-mediated diseases. It is engineered using an Fc-optimized design for selective depletion of pro-inflammatory antigen-presenting cells (APCs), resulting in potent suppression of pathogenic T-cell responses (both CD4+ and CD8+), while markedly increasing the induction of regulatory T-cell phenotypes. OX118 is in early clinical development, with a first-in-human Phase 1 trial underway in healthy volunteers to assess its safety, tolerability, and pharmacokinetics. Preclinical studies have demonstrated OX118’s superior efficacy in modulating immune responses and survival benefits in severe disease models such as graft-versus-host disease. The primary mechanism involves blocking and depleting cells expressing the OX40 ligand (OX40L), a key mediator of immune cell communication and activation in autoimmunity and inflammatory settings[1][3][5][7].